Matrix metalloproteinases and tissue inhibitors of metalloproteinases in sera and tissue of patients with Dupuytren's disease

被引:45
|
作者
Ulrich, D [1 ]
Hrynyschyn, K
Pallua, N
机构
[1] Rhein Westfal TH Aachen, Univ Hosp, Dept Plast Surg & Hand Surg, Burn Ctr, Aachen, Germany
[2] Ev Elisabeth Hosp Trier, Dept Plast Surg & Hand Surg, Trier, Germany
关键词
D O I
10.1097/01.PRS.0000081462.40448.49
中图分类号
R61 [外科手术学];
学科分类号
摘要
Dupuytren's contracture is a fibroproliferative disorder characterized by progressive deposition of mature collagen fibers. In other fibrotic diseases affecting organs such as the liver, lung, heart, and skin, matrix metalloproteinases (MMPs) and their natural inhibitors, the tissue inhibitors of metalloproteinases (TIMPs), play an important role. In this study, serum concentrations of MMP-1, MMP-2, MMP-9, TIMP-1, and TIMP-2 were determined in 22 patients (five women and 17 men; average age, 67 +/- 11 years) with Dupuytren's disease using all enzyme-linked immunosorbent assay. Tissue samples were obtained for standard histological and immunohistochemical analyses. Sera and samples of palmar fascia from 20 patients (13 women and seven men; average age, 60 +/- 15 years) who had undergone hand surgery for carpal tunnel syndrome were used as the control group. Statistical analysis was performed using the Mann-Whitney test. Patients with Dupuytren's contracture presented with a TIMP-1 concentration of 437 +/- 160 ng/nA, a significantly higher TIMP-1 concentration than that seen in the control patients, who had a concentration of 321 +/- 70 ng/ml (p < 0.05). Patients with a proliferative active disease (n = 14) had a significantly higher TIMP-1 concentration (525 +/- 136 ng/ml) than patients (n = 8) with a contracture in the late involutional and residual phase (286 +/- 41 ng/ml; p < 0.05). There were no significant differences in the TIMP-2, MMP-1, MMP-2, and MMP-9 serum concentrations between patients with palmar fibromatosis and the control group. Patients with Dupuytren's disease had a significantly lower MMP-to-TIMP ratio (1.1 +/- 0.3; p < 0.05) than the control group (1.5 +/- 0.35). Patients with all active palmar fibromatosis presented a significantly (p < 0.05) reduced ratio (1 +/- 0.2) compared with those in later phases (1.4 +/- 0.3). TIMP-1 and TIMP-2 could be detected in tissue of patients with Dupuytren's contracture, with an accumulation in proliferative areas. MMPs could be detected locally in Dupuytren's tissue ill a few patients, with less positive staining than for TIMPs. In the control group, there was just little or no staining for TIMPs and MMPs. The data indicate that the physiological balance between MMPs and their natural inhibitors is disturbed in patients with a proliferative active Dupuytren's disease. The decrease in the systemic MMP-to-TIMP ratio call cause increased synthesis and deposition of collagen, leading to palmar fibromatosis.
引用
收藏
页码:1279 / 1286
页数:8
相关论文
共 50 条
  • [1] MATRIX METALLOPROTEINASES AND TISSUE INHIBITORS OF MATRIX METALLOPROTEINASES IN THE PATHOGENESIS OF PEYRONIE'S DISEASE
    Campbell, J.
    DeYoung, L.
    Chung, E.
    Brock, G.
    JOURNAL OF SEXUAL MEDICINE, 2016, 13 (05): : S11 - S11
  • [2] Matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in kidney disease
    Zakiyanov, Oskar
    Kalousova, Marta
    Zima, Tomas
    Tesar, Vladimir
    ADVANCES IN CLINICAL CHEMISTRY, VOL 105, 2021, 105 : 141 - 212
  • [3] Matrix metalloproteinases and their tissue inhibitors
    Timms, PM
    Campbell, S
    Srikanthan, V
    Price, CP
    BIOMARKERS OF DISEASE: AN EVIDENCE-BASED APPROACH, 2002, : 379 - 388
  • [4] Transcriptional control of matrix metalloproteinases and the tissue inhibitors of matrix metalloproteinases
    Borden, P
    Heller, RA
    CRITICAL REVIEWS IN EUKARYOTIC GENE EXPRESSION, 1997, 7 (1-2): : 159 - 178
  • [5] Structural basis of matrix metalloproteinases and tissue inhibitors of metalloproteinases
    Klaus Maskos
    Wolfram Bode
    Molecular Biotechnology, 2003, 25 : 241 - 266
  • [6] Structural basis of matrix metalloproteinases and tissue inhibitors of metalloproteinases
    Maskos, K
    Bode, W
    MOLECULAR BIOTECHNOLOGY, 2003, 25 (03) : 241 - 266
  • [7] Balance between Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases
    Yalcinkaya, Emre
    Celik, Murat
    CARDIOLOGY, 2014, 128 (04) : 316 - 316
  • [8] Matrix metalloproteinases and tissue inhibitors of metalloproteinases in ovarian function
    McIntush, EW
    Smith, MF
    REVIEWS OF REPRODUCTION, 1998, 3 (01): : 23 - 30
  • [9] MATRIX METALLOPROTEINASES AND TISSUE INHIBITORS OF METALLOPROTEINASES IN HUMAN GLIOMAS
    NAKANO, A
    TANI, E
    MIYAZAKI, K
    YAMAMOTO, Y
    FURUYAMA, JI
    JOURNAL OF NEUROSURGERY, 1995, 83 (02) : 298 - 307
  • [10] Expression of matrix metalloproteinases and their inhibitors in cords and nodules of patients with Dupuytren’s disease
    Dietmar Ulrich
    Franziska Ulrich
    Andrzej Piatkowski
    Norbert Pallua
    Archives of Orthopaedic and Trauma Surgery, 2009, 129 : 1453 - 1459